Vaxcyte, Inc. (FRA:5VA)

Germany flag Germany · Delayed Price · Currency is EUR
40.80
+0.20 (0.49%)
At close: Nov 28, 2025
-54.16%
Market Cap5.13B
Revenue (ttm)n/a
Net Income (ttm)-560.13M
Shares Outn/a
EPS (ttm)-4.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume35
Open40.80
Previous Close40.60
Day's Range40.80 - 40.80
52-Week Range24.60 - 89.50
Betan/a
RSI57.48
Earnings DateFeb 25, 2026

About Vaxcyte

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 414
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5VA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.